Filing Details
- Accession Number:
- 0001209191-21-040324
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-14 18:18:31
- Reporting Period:
- 2021-06-11
- Accepted Time:
- 2021-06-14 18:18:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1661460 | Poseida Therapeutics Inc. | PSTX | Biological Products, (No Disgnostic Substances) (2836) | 472846548 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1766302 | A. Matthew Spear | C/O Poseida Therapeutics, Inc. 9390 Towne Centre Drive, Ste 200 San Diego CA 92121 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-06-11 | 4,000 | $1.32 | 20,485 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-06-11 | 4,000 | $9.44 | 16,485 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-06-11 | 4,000 | $0.00 | 4,000 | $1.32 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 119,861 | 2026-06-19 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.55 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within therange set forth in this footnote.
- The stock option is fully vested and exercisable.
Billionaire Hedge Funds
